Zenon Biotech

Zenon Biotech is a preclinical stage biotech company developing novel inhibitors of aberrant cell behavior for the treatment of cancer and fibrosis. Their science relies on mechano-biology, the study of how cells detect and react to changes in the extracellular matrix, such as tissue stiffness, resulting in cell behavioral changes. Evidence shows that this tissue stiffness can drive disease progression in diseases like cancer and fibrosis. Zenon’s machano-therapeutics are designed to modulate this signaling pathway, resulting from the sensing of tissue stiffness, by targeting the receptors called mechano-sensors. Cells in cancer and fibrosis have an irregular upregulation of these mechano-receptors, allowing a selective targeting of these cells and directed therapeutic improvements.

Jobs: